USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Baili-bio (CHENGDU) Pharmaceutical Co., Ltd.

USPTO PatentsView assignee record - 7 granted patents across 4 technology areas, recorded in grant years 2022–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).

RSS updates for this company

The verdict

According to USPTO PatentsView, Baili-bio ranks #34,400 of 49,997 tracked US assignees by granted-patent volume, with 7 patents across 4 technology areas.

#34,400
of 49,997 US assignees by volume
Top 32%
by Innovation Score (42.0/100)
12.9
avg claims per patent

USPTO PatentsView assignee plate

Corpus R34400 · Foreign Corporation #34,400 · 7 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

  • GRANTS-MICRO 7 grants
  • MID-PACK #34,400/49,997
  • PHOTO-FINISH Axon Pressure Products
  • CPC-NARROW C07K · 4 areas
  • INNOV-PAR 42.0/100
  • CLAIMS-RICH 12.9 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • SPAN-YRS 2022–2024 · 3y
  • BOOK-RICH 9/10 fields

Nearest grant-volume peer: Axon Pressure Products, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Baili-bio

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Baili-bio's Innovation Score is 42.0/100 (top 32% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Where Baili-bio's grants concentrate

Baili-bio (CHENGDU) Pharmaceutical Co., Ltd. is a focused PatentsView assignee: 4 CPC subclasses with 100% of grants classified under C07K (Peptides). Peak complete grant year is 2022 (3 grants) versus a trough of 1 in 2024. By volume, Baili-bio sits between Axon Pressure Products, Inc. and Balsam International Unlimited Company.

Baili-bio's three-year grant acceleration

Baili-bio (CHENGDU) Pharmaceutical Co., Ltd. shows 7 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Baili-bio's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Baili-bio holds 7 patents at rank #34,393, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Baili-bio

By rank, the assignees closest to #34,393 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in Baili-bio's primary technology class.

Baili-bio's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

42 Top 32% higher than 68% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0.511.522.533.5 202220232024 1
USPTO utility patent grants by year · 2022–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.

View data table
Baili-bio (CHENGDU) Pharmaceutical Co., Ltd. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2022 3 42.9%
2023 3 42.9%
2024 1 14.3%

Where it ranks

Overall rank by patents

#34,400

of 49,997 tracked assignees

Innovation Score

42.0 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Baili-bio (CHENGDU) Pharmaceutical Co., Ltd.'s patent record in context - here's where to go next.

  • Baili-bio (CHENGDU) Pharmaceutical Co., Ltd.'s lead technology class is C07K (Peptides), 100% of its portfolio - see every assignee active in that class. Explore C07K
  • Ranked #34,400 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Baili-bio (CHENGDU) Pharmaceutical Co., Ltd. against Axon Pressure Products, Inc., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 42.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.